Get started

ACRX

$ACRX to 7$ In December AcelRx published clinical data in „The Journal of Universal Surgery“ titled „A Medication Use Evaluation of Sufentanil Sublingual Tablet 30 mcg for the Perioperative Management of Surgical Pain“. What is DSUVIA? According to AcelRx DSUVIA is a recently approved drug „indicated for use in adults in certified medically supervised healthcare settings for the management of acute pain severe enough to require an opiod analgesic.“ The US army recently awarded AcelRX with a ~$3.6M contract in order to purchase for the drug DSUVIA to support a study made by the US army as well as purchases for the stocking of their medical equipment for troop deployment and additional purchases by other branches of the military following the recent approval of DSUVIA. AcelRx estimates that DSUVIA has the potential to reach over $1B in annual revenues. To put that into perspective - in 2019 they posted revenues of only $2.29M. Technical Analysis is currently at a crucial point as price will soon break the symetric triangle in either direction - it will most likely be a movement in the upper direction as the Fibo Levels of the recent upwards trend as well as the $2.00 level act as strong support in combination with the good fundamental data. Most institutional investors also seem to hold a bullish bias according to the data my broker provides.
ALong
by EnisGuriGashi
3
ACRX - Perfect Trend Bounce 0.168 Levels On DailyAcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer. SHORT INTEREST 15.09M 07/15/19 Average Recommendation: BUY Average Target Price: 7.71 P/E Current -3.02 P/E Ratio (with extraordinary items) -3.90
ALong
by DEXWireNews
Potential Bear Flag ACRX PharmaLooking at the 1 day chart shows a clear bear flag forming over the past months. Criteria to enter trade: Clear break of lower (red) long term support line. This is an ideal situation to use a Sell Stop Order (where a short order is placed in book at a price below the current market price) Targets: Once support is broken looking for a $1.95 target.(green) --------- In the case we see a bounce off the lower support line (red) I will be looking to enter a long position with a target at $4.00
AShort
by nowewithoutuandi
Long ACRX: Bullish Bat at Trendline SupportACRX is nearing the completion of a bullish bat pattern on the daily chart. The PRZ falls in a significant support zone and may be confluent with support from a 3-month trendline. 3 Missed weekly pivots sit above price to add to the bullish bias. Entry is placed at the bottom of the PRZ with target at .618CD and SL below the 1.13XA fib level. Confluence in the PRZ: Bullish bat pattern completion 4BC projection AB=CD 3 month trendline support Missed weekly pivots above price S/R Zone
ALong
by glennmercer